BioReliance has named Charles Harwood, who currently is executive chairman, to the post of interim CEO in the wake of the departure of former CEO Tim Derrington.
 
BioReliance, which Invitrogen sold in April to Avista Capital Partners for $210 million, noted that since June three senior executives have joined the company, including David Onions as CSO, David Walker as CFO, and Darryl Goss as VP of Global Process Excellence.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.